



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AKI-603

Item No. 40840

CAS Registry No.: 1432515-73-5
Formal Name: 6-(4-methyl-1-piperazinyl)-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-(4-nitrophenyl)-2,4-pyrimidinediamine
MF: C₁₉H₂₃N₉O₂
FW: 409.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AKI-603 is supplied as a solid. A stock solution may be made by dissolving the AKI-603 in the solvent of choice, which should be purged with an inert gas. AKI-603 is slightly soluble (0.1-1 mg/ml) in ethanol and sparingly soluble (1-10 mg/ml) in DMSO.

Description

AKI-603 is an inhibitor of Aurora A kinase ($IC_{50} = 12 \text{ nM}$).¹ It reduces the proliferation of HL-60 promyeloblast leukemia cells, K562 chronic myeloid leukemia (CML) cells, U937 lymphoma monocytes, MOLT-4 T cell lymphoblasts, and MCF-7 and MDA-MD-231 breast cancer cells (IC_{50} s = 69, 137, 43, 18, 424, and 84 nM, respectively). AKI-603 (600 nM) induces cell cycle arrest at the G₂/M phase in SUM149 triple negative breast cancer cells.² It decreases the endogenous elevated levels of β -catenin, c-Myc, SOX2, Nanog, and octamer-binding transcription factor 4 (Oct4) in epirubicin-resistant MCF-7 breast cancer cells (MCF-7/Epi) when used at a concentration of 5 μ M. AKI-603 (78 nM) reduces the number of mammospheres formed by SUM149 cells. *In vivo*, AKI-603 (50 mg/kg per day) decreases tumor volume and weight without reducing body weight in an MCF-7/Epi mouse xenograft model.

References

1. Luo, Y., Deng, Y.-Q., Wang, J., *et al.* Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors. *Eur. J. Med. Chem.* **78**, 65-71 (2014).
2. Zheng, F.-M., Long, Z.-J., Hou, Z.-J.L., Y., *et al.* A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. *Mol. Cancer Ther.* **13(8)**, 1991-2003 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/29/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM